The psychostimulant modafinil facilitates water maze performance and augments synaptic potentiation in dentate gyrus

Modafinil is a psychostimulant drug used widely for the treatment of narcolepsy, which also has additional positive effects on cognition. Here, we investigate the effects of modafinil on behavioural performance and synaptic plasticity in rats. Improved acquisition in the water maze task was observed...

Full description

Saved in:
Bibliographic Details
Published inNeuropharmacology Vol. 59; no. 1; pp. 9 - 19
Main Authors Tsanov, Marian, Lyons, Declan G., Barlow, Sally, González Reyes, Rodrigo E., O’Mara, Shane M.
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.07.2010
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Modafinil is a psychostimulant drug used widely for the treatment of narcolepsy, which also has additional positive effects on cognition. Here, we investigate the effects of modafinil on behavioural performance and synaptic plasticity in rats. Improved acquisition in the water maze task was observed in animals that underwent chronic treatment with modafinil. We found that the distance traveled and escape latency were reduced after the first day in chronically-treated rats, compared to controls. Importantly, swim velocity was similar for both groups, excluding pharmacological effects on motor skills. We also found that modafinil increases synaptic plasticity in the dentate gyrus of urethane-anaesthetized rats; modafinil induced a robust augmentation of the population spike, evident after application of 2 bursts of 200 Hz high-frequency stimulation. Furthermore, the modafinil-dependent enhancement of postsynaptic potentials correlated selectively with theta rhythm augmentation. We propose that modafinil may facilitate hippocampal-associated spatial representation via increased theta-related hippocampal plasticity.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0028-3908
1873-7064
DOI:10.1016/j.neuropharm.2010.03.010